GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (FRA:0PT) » Definitions » Research & Development

Prothena (FRA:0PT) Research & Development : €194.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Prothena Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Prothena's Research & Development for the three months ended in Mar. 2025 was €47.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €194.0 Mil.

Prothena Research & Development Historical Data

The historical data trend for Prothena's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Research & Development Chart

Prothena Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.56 72.82 127.97 202.26 212.51

Prothena Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.99 53.43 45.70 47.91 47.00

Prothena Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €194.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena  (FRA:0PT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prothena Research & Development Related Terms

Thank you for viewing the detailed overview of Prothena's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Prothena Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (FRA:0PT) » Definitions » Research & Development
Comparable Companies
KURA COGT MGTX VERV STOK TYRA FTRE SION RLAY SVRA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
PRTA:USA 0Y3M:UK
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Website
https://www.prothena.com
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Prothena Headlines

No Headlines